MHRA - Innovative Licensing and Access Pathway

7th April 2021

A new pathway supporting innovative approaches to the safe, timely and efficient development of medicines to improve patient access.

Published: 30th March 2021

The Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications and repurposed medicines.

Horizon scanning and regulatory science will make sure the pathway is at the forefront of cutting-edge developments and has the framework to develop evidence-based practice as new technologies and methods emerge.

The ILAP is open to both commercial and non-commercial developers of medicines (UK based and or global). It comprises of an Innovation Passport designation, a Target Development Profile (TDP) and provides applicants with access to a toolkit to support all stages of the design, development and approvals process.

The ILAP provides you with opportunities for enhanced regulatory and other stakeholder input.

Click here to access guidance

Back to News Archive